George Reiss, MD
Ophthalmology · Glendale, AZNPI 1619927969
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Glaukos Corporation at 32.2% of the total. Among ophthalmology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 258 payments — averaging $284.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$24K
- Aerie Pharmaceuticals, Inc.$20K
- W. L. Gore & Associates, Inc.$14K
- AbbVie$5K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$5K
- Nova Eye, Inc.$2K
- plus $4K from 14 others
Across 323 payments — averaging $3691.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$1M
- AbbVie$149K
- Alcon Research LLC$20K
What the payments were for
- Consulting fees$33,65046%
- Speaking & faculty fees$24,00233%
- Travel & lodging$5,9768%
- Food & beverage$8,69512%
- Education$490%
- Gifts$450%
- Other$1,0771%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 55 | $23,686 |
| Aerie Pharmaceuticals, Inc. | 45 | $20,152 |
| W. L. Gore & Associates, Inc. | 19 | $13,955 |
| AbbVie(2 entities) | 42 | $5,307 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $5,123 |
| Nova Eye, Inc. | 4 | $1,713 |
| Carl Zeiss Meditec USA, Inc. | 8 | $1,245 |
| Alcon | 28 | $798 |
| Bausch & Lomb Americas Inc. | 13 | $339 |
| Novartis | 5 | $192 |
| Sight Sciences, Inc. | 3 | $188 |
| Ocular Therapeutix, Inc. | 2 | $160 |
| Rxsight Inc | 2 | $155 |
| NEW World Medical,inc. | 8 | $133 |
| Imperative Care, Inc | 1 | $96 |
| Dompe US, Inc. | 1 | $95 |
| Ivantis, Inc | 2 | $71 |
| Thea Pharma Inc. | 2 | $34 |
| Kala Pharmaceuticals, Inc. | 2 | $32 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$19,305
- Rhopressa$14,168
- Product in Development$13,776
- iDose$11,573
- iStent inject W$5,000
- VYZULTA$4,900
- DURYSTA$3,150
- PRESERFLO MicroShunt$2,649
- CLARUS$1,054
- CIRRUS HD-OCT$948
- FORUM$948
- Humphrey HFA$948
- IOLMaster 700$948
- iDoseTR$444
- XEN$207
- XEN GLAUCOMA TREATMENT SYSTEM$149
- RXSIGHT CONTACT LENS$135
- RXSIGHT INJECTOR CARTRIDGE$135
- RXSIGHT INJECTOR HANDPIECE$135
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$135
How this compares
$73,493 in reported general payments places this provider in the 95th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 245 | $97,012 |
| RocklatanNetarsudil Mesylat/Latanoprost | 153 | $70,150 |
| VyzultaLatanoprostene Bunod | 113 | $49,761 |
| CombiganBrimonidine Tartrate/Timolol | 54 | $18,054 |
| Alphagan PBrimonidine Tartrate | 42 | $13,185 |
| Prednisolone Acetate | 369 | $13,103 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 55 | $11,948 |
| RhopressaNetarsudil Mesylate | 25 | $9,191 |
| IyuzehLatanoprost/Pf | 17 | $7,675 |
| Travoprost | 42 | $6,840 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 387 | $6,404 |
| TafluprostTafluprost/Pf | 25 | $5,591 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 30 | $5,165 |
| Latanoprost | 467 | $4,371 |
| Loteprednol Etabonate | 23 | $3,818 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $5,307 | $128,252341 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $20,152 | $79,340178 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $339 | $49,761113 claims |
| AlconSimbrinza | $798 | $11,94855 claims |
| Thea Pharma Inc.Iyuzeh | $34 | $7,67517 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $5,123 | $3,81823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 310 ophthalmology providers in Arizona.
Other ophthalmology in Glendale
- Shamil PatelGlendale$116K
- Wendy HuangGlendale$73K
- Anne FloydGlendale$11K
- Warren HillMesa$1.1M
- Mark BarakatScottsdale$794K
- Anne ZakiSun City West$518K
- Pravin DugelPhoenix$176K
- Derek KunimotoMesa$138K
- Yuri McKeeMesa$100K
- Nishi ShahPhoenix$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.